ClinicalTrials.gg
CompletedNCT06656026Updated Nov 17, 2025

Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A

A Phase 2 interventional study of ZSP1273 granules in Influenza a, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Enrollment
137th of 157
72 · median 360
Started
2024
with 16 others
Phase 2
16 of 173
1 open now
Registered
137th of 173
by date
Lead sponsor
5 of 173
Guangdong Raynovent Biotech Co., Ltd

Among the 173 studies in Influenza, Human with a site in China, this one is the 137th largest by enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2024, is one of 16 in phase 2, and was the 137th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of the trial is to investigate safety,pharmacokinetics and pharmacodynamics of ZSP1273 granules

03

Conditions studied

  • Influenza a

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written /assent prior to the predose examinations appropriately.
  2. Male or female subjects aged ≥ 2 to ≤17 years at the time of signing the informed consent form.
  3. Subjects with a diagnosis of influenza virus infection confirmed by all of the following:

    • Positive rapid antigen test (RAT) for influenza with nasal or throat swabs;
    • The time interval between the onset of symptoms and enrollment is 72 hours or less;
    • Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present

Exclusion criteria

Exclusion Criteria:

  1. Subjects with severe influenza virus infection;
  2. Subjects with any medical history in gastrointestinal that interferes with the absorption of drugs;
  3. Immunodeficiency,including malignant tumor,organ or marrow transplant, [HIV] infection,or patients receiving therapy 3 months prior to enrollment;
  4. Have received any other products within 3 months prior to dosing;
  5. Positive urine pregnancy test;
  6. Subjects with concurrent infections requiring antimicrobial therapy;
  7. Subjects who are considered inappropriate for the study by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ZSP1273(Arm a)

    * ≥2 ,\<6 year old,dose 1 QD;5day * ≥6 ,\<12 year old,dose 2 QD;5day * ≥12,≤17 year old,dose 3 QD;5day

    Drug: ZSP1273 granules

  • Experimental
    ZSP1273(Arm b)

    * ≥2 ,\<6 year old,dose 4 QD;5day * ≥6 ,\<12 year old,dose 5 QD;5day * ≥12,≤17 year old,dose 6 QD;5day

    Drug: ZSP1273 granules

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of ZSP1273

    Time frame: DAY1~5

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: DAY1~29

  2. Time to alleviation of influenza symptoms (duration of influenza)

    Time frame: DAY1~29

  3. Percentage of subjects with virus titer detected

    Time frame: DAY1~29

07

Study locations

1 site
  • The First Affiliated Hospital Of Guangzhou Medical University
    Guangzhou, Guangdong, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jun 2025, 7 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 7 months is close to that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 24, 2024
StartActual
Nov 30, 2024
Primary completionActual
Jun 30, 2025
CompletionActual
Jul 31, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06656026
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Nov 30, 2024
Primary completion
Jun 30, 2025
Completion
Jul 31, 2025
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion